MINI FUTURE SHORT - IDORSIA | Real-time Bid/Ask 10:22:19 2024-05-17 am EDT | ||
| 4.72 CHF / 4.74 CHF | +0.42% |
|
| Current month | -2.28% | ||
| 1 month | -1.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 4.71 | -0.21% |
| 24-05-13 | 4.72 | -0.84% |
Delayed Quote Swiss Exchange
Last update May 15, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | IDORSIA LTD |
| Issuer | 
BNP Paribas
|
| QQBABP | |
| ISIN | CH0582885759 |
| Date issued | 2021-03-01 |
| Strike | 25.76 CHF |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | CHF |
Technical Indicators
| Highest since issue | 4.96 CHF |
|---|---|
| Lowest since issue | 1.25 CHF |
| Spread | 0.02 CHF |
| Spread % | 0.42% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.352
CHF
Average target price
1.724
CHF
Spread / Average Target
-26.71%
- Stock Market
- Certificates
- QQBABP Certificat